90224-84-3

Usage

Molecular structure

2-(4-bromophenyl)-2H-1,2,3-triazole-4-carboxylic acid consists of a triazole ring and a carboxylic acid group, with a bromine atom attached to the phenyl ring.

Functional groups

The compound contains a triazole ring, a carboxylic acid group, and a bromophenyl group.

Usage

It is commonly used in organic synthesis and medicinal chemistry as a building block for the preparation of various pharmaceuticals and biologically active molecules.

Importance in drug development

The presence of the bromophenyl group and the triazole ring makes 2-(4-bromophenyl)-2H-1,2,3-triazole-4-carboxylic acid a valuable intermediate in the development of potential drugs and agrochemicals.

Application in material production

It is an important component in the production of advanced materials.

Role in drug design and discovery

The compound is utilized in the study of structure-activity relationships in drug design and discovery.

Upstream product

• 91348-65-1 ethyl 2-(4-bromophenyl)-2H-1,2,3-triazole-4-carboxylate 
• 5467-74-3 4-Bromophenylboronic acid 
• 13306-99-5 2-phenyl-2H-[1,2,3]triazole-4-carboxylic acid 

Downstream Products

• 1312603-88-5 C₁₈H₁₁BrN₆S 
• 1312603-89-6 C₁₈H₁₀Br₂N₆S 
• 1312603-90-9 C₁₈H₁₀BrClN₆S 
• 1312603-97-6 C₁₈H₁₀Br₂N₆S 
• 1312603-98-7 C₁₈H₉Br₃N₆S 
• 1312603-99-8 C₁₈H₉Br₂ClN₆S 
• 1312604-07-1 C₁₈H₁₀BrIN₆S 
• 1312604-08-2 C₁₈H₉Br₂IN₆S 
• 1312604-09-3 C₁₈H₉BrClIN₆S 
• 1312603-86-3 2-amino-5-[2-(4-bromophenyl)-2H-1,2,3-triazol-4-yl]-1,3,4-thiadiazole 

Relevant academic research and scientific papers

SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS

The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. R1 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, 5- to 6-membered heteroaryl or phenyl; R2 is hydrogen or alkyl; A is 5-membered heteroaryl; Z is 6- to 10-membered aryl or 5- to 10-membered heteroaryl; all groups being optionally substituted.

2H-1,2,3-Triazole-Based Dipeptidyl Nitriles: Potent, Selective, and Trypanocidal Rhodesain Inhibitors by Structure-Based Design

Macrocyclic inhibitors of rhodesain (RD), a parasitic cysteine protease and drug target for the treatment of human African trypanosomiasis, have shown low metabolic stability at the macrocyclic ether bridge. A series of acyclic dipeptidyl nitriles was developed using structure-based design (PDB ID: 6EX8). The selectivity against the closely related cysteine protease human cathepsin L (hCatL) was substantially improved, up to 507-fold. In the S2 pocket, 3,4-dichlorophenylalanine residues provided high trypanocidal activities. In the S3 pocket, aromatic residues provided enhanced selectivity against hCatL. RD inhibition (Ki values) and in vitro cell-growth of Trypanosoma brucei rhodesiense (IC50 values) were measured in the nanomolar range. Triazole-based ligands, obtained by a safe, gram-scale flow production of ethyl 1H-1,2,3-triazole-4-carboxylate, showed excellent metabolic stability in human liver microsomes and in vivo half-lives of up to 1.53 h in mice. When orally administered to infected mice, parasitaemia was reduced but without complete removal of the parasites.